Medical solutions company DyAnsys Inc revealed on Tuesday the receipt of clearance from the US Food and Drug Administration for its Drug Relief wearable device to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics.
An estimated 11.5 million Americans age 12 and older misused prescription pain medicine in 2016, according to the Substance Abuse and Mental Health Services Administration. More than 2.5 million Americans suffer from opioid use disorder, according to the National Institutes on Drug Abuse.
According to the company, the Drug Relief is available for providers to prescribe for use during opioid detoxification. This wearable device sends electrical pulses through tiny needles inserted in the ear to alleviate symptoms, including anxiety, agitation, depression, nausea, opiate cravings and more. The percutaneous electrical nerve field stimulator is designed to administer auricular neurostimulation treatment over 120 hours.
In conjunction, the non-addictive Drug Relief treatment allows for continuous nerve stimulation over five days, while offering the patient comfort and mobility. According to providers, patients may see a reduction in the symptoms of opioid withdrawal within 30 to 60 minutes of beginning treatment, said the company.
The company disclosed the objective of Drug Relief is to ease symptoms, while opioids are cleared from a patient's system. It can be used to help stabilise a patient during the early stages of withdrawal without side effects. Stabilisation is a necessary first step before treating the patient with medication-assisted therapies like naltrexone. The device eases the process of detoxification, which is the first step in a comprehensive rehabilitation programme.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project